Wikipedia -WSS

Wikipedia

author：focus 2025-09-28 13:23:41 - browse：67

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Colonoscopy at 40? Study finds a possible benefit

focus

WSS

Why we need to separate burnout from moral injury in health care

New research casts further doubt on a common procedure used with IVF

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Living with Fabry disease, a condition that causes chronic pain

Why ADHD is under

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

What does generative AI mean for health care? We asked experts

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Supreme Court strikes down use of affirmative action

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Bright Health sells Medicare Advantage business to Molina

Charles Manson follower Leslie Van Houten released from prison after 53 years

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Palantir health business leans on meeting customers’ needs

Jerome Adams on the need for new antivirals for Covid

#NeedHerScience: shining a light on gender disparities in medicine

Wikipedia

Why are elite athletes different? Take a look at their microbes

Living with Fabry disease, a condition that causes chronic pain

What to know about OceanGate, the company behind the missing Titanic submersible

Beach reads and more: STAT's 2023 summer book list

Why are elite athletes different? Take a look at their microbes

#NeedHerScience: shining a light on gender disparities in medicine

explore

focus

explore

knowledge